Preclinical studies in mice have shown that optimal anti-tumor activity of anti-CTLA-4 antagonist antibodies required co-engagement of FcγRs expressed by tumor-associated effector cells [15–17, 47]. This evidence concerns the gene CTLA4 and neoplasm.